Cempra Pharmaceuticals announces schedule of poster presentations at ECCMID 2010

Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010.

One poster will present Phase 1 multi-dose clinical results for CEM-101, a next-generation oral and intravenous macrolide.  Four additional presentations on CEM-101 will present results on the compound's in vitro activity against a variety of bacterial pathogens, including drug-resistant strains.  A sixth poster will present in vitro activity of TAKSTA (CEM-102) against European gram positive isolates, including staphylococci, streptococci and enterococci.  TAKSTA (sodium fusidate) is a highly active antibiotic against methicillin-resistant Staphylococcus aureus (MRSA).  It is in development in the U.S. for acute bacterial skin structure infections (aBSSI) employing a proprietary front-loading oral dosing regimen.  All six posters will be presented during the poster session scheduled for 12:30 to 1:30 p.m. CET on Sunday, April 11.

Cempra Pharmaceuticals ECCMID 2010 Schedule At-A-Glance

Sunday, April 11, 2010

• Poster presentation: "CEM-101, a novel fluoroketolide, tested against European clinical isolates from 2009 (first-year surveillance results)"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 901

R. Jones, D. Farrell, H. Sader, M. Stilwell, M. Castaheira (JMI Laboratories, North Liberty, IA, USA)

• Poster Presentation: "Multiple dose pharmacokinetics and safety of CEM-101, a new fluoroketolide, in healthy subjects"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 902

J.G. Still, K. Clark, T. Degenhardt, D. Scott, P. Fernandes (Cempra Pharmaceuticals, Chapel Hill, USA)

• Poster Presentation: "CEM-101, a novel ketolide; in vitro activity against Legionella pneumophila"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 903

J. Dubois(1), P. Fernandes(2) ((1)M360, Sherbrooke, Canada, (2)Cempra Pharmaceuticals Inc., Chapel Hill, USA)

• Poster Presentation: "CEM-101, a novel ketolide, in vitro activity against resistant strains of Streptococcus pnuemoniae and Haemophilus influenza"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 904

J. Dubois(1), P. Fernandes(2) ((1)M360, Sherbrooke, Canada, (2)Cempra Pharmaceuticals Inc., Chapel Hill, USA)

• Poster Presentation: "Expanded studies of CEM-101, a novel fluoroketolide, tested against invasive isolates of N. meningitidis, including flouroquinolone-non-susceptible resistant strains"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 905

R. Jones, D. Biedenbach, L. Woosley, G. Gerken, M. Castaheira (JMI Laboratories, North Liberty, IA, USA)

• Poster Presentation: "CEM-102 (fusidic acid) in vitro activity and evaluation of molecular resistance mechanisms among European Gram-positive isolates, 2008-2009"

Time: On display 12:30 to 13:30 p.m. CET, Poster # 906

M. Castanheira, D. Farrell, M. Janechek, R. Jones

(JMI Laboratories, North Liberty, IA, USA)